Literature DB >> 31498447

Real-world evidence for increased deep neck infection risk in patients with rheumatoid arthritis.

Geng-He Chang1,2,3, Meng-Chang Ding1, Yu-Cheng Chen4, Yao-Hsu Yang5,6, Chia-Yen Liu2, Pey-Jium Chang7,3, Chuan-Pin Lee2, Meng-Hung Lin2, Cheng-Ming Hsu1,6, Ching-Yuan Wu1,5,6, Ko-Ming Lin8,9, Ming-Shao Tsai1,2,3.   

Abstract

OBJECTIVE: To investigate the association between rheumatoid arthritis (RA) and deep neck infection (DNI). STUDY
DESIGN: Retrospective cohort study.
METHODS: Patients newly diagnosed with RA between 2000 and 2011 were identified from the National Health Insurance Research Database in Taiwan. Moreover, patients without RA were randomly selected and matched at a 1:4 ratio by age, sex, urbanization level, income, and diabetes mellitus. The patients were followed up until death or the end of the study period (December 31, 2013). The primary outcome was the occurrence of DNI.
RESULTS: In total, 30,207 patients with RA and 120,828 matched patients without RA were enrolled. Patients with RA had a significantly higher cumulative incidence of DNI than those without RA (P < 0.001). The adjusted Cox proportional hazard model demonstrated that RA was significantly associated with a higher incidence of DNI (hazard ratio: 2.80, 95% confidence interval: 2.26-3.46, P < 0.001). Therapeutic methods (surgical or nonsurgical) did not differ significantly between the patients with RA-DNI and with non-RA-DNI. Patients with RA-DNI had higher rates of tracheostomy, mediastinitis, mediastinitis-related mortality, and mortality than patients with non-RA-DNI, although these differences were without statistical significance. RA patients receiving no therapy experienced higher rates of DNI compared with those receiving methotrexate alone, disease-modifying antirheumatic drugs, or biologic therapies.
CONCLUSION: This study is the first to investigate the association between RA and DNI. We conclude RA is an independent predisposing factor for DNI. LEVEL OF EVIDENCE: 4 Laryngoscope, 130:1402-1407, 2020.
© 2019 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Abscess; autoimmune diseases; cellulitis; population-based study; predisposing factor

Mesh:

Substances:

Year:  2019        PMID: 31498447     DOI: 10.1002/lary.28272

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  5 in total

1.  Sleep Apnea and Risk of Influenza-Associated Severe Acute Respiratory Infection: Real-World Evidence.

Authors:  Ming-Shao Tsai; Hung-Chin Chen; Hsueh-Yu Li; Yao-Te Tsai; Yao-Hsu Yang; Chia-Yen Liu; Yi-Chan Lee; Cheng-Ming Hsu; Li-Ang Lee
Journal:  Nat Sci Sleep       Date:  2022-05-10

2.  The Association Between Decompensated Liver Cirrhosis and Deep Neck Infection: Real-World Evidence.

Authors:  Ming-Shao Tsai; Geng-He Chang; Wei-Ming Chen; Chia-Yen Liu; Meng-Hung Lin; Pey-Jium Chang; Tsung-Yu Huang; Yao-Te Tsai; Ching-Yuan Wu; Cheng-Ming Hsu; Yao-Hsu Yang
Journal:  Int J Environ Res Public Health       Date:  2019-10-12       Impact factor: 3.390

3.  Allergic Rhinitis and Laryngeal Pathology: Real-World Evidence.

Authors:  Yun-Ting Wang; Geng-He Chang; Yao-Hsu Yang; Chia-Yen Liu; Yao-Te Tsai; Cheng-Ming Hsu; Yi-Chan Lee; Li-Ang Lee; Pei-Rung Yang; Ming-Shao Tsai; Hsueh-Yu Li
Journal:  Healthcare (Basel)       Date:  2021-01-03

4.  High Risk of Peritonsillar Abscess in End-Stage Renal Disease Patients: A Nationwide Real-World Cohort Study.

Authors:  Geng-He Chang; Ang Lu; Yao-Hsu Yang; Chia-Yen Liu; Pey-Jium Chang; Chuan-Pin Lee; Yao-Te Tsai; Cheng-Ming Hsu; Ching-Yuan Wu; Wei-Tai Shih; Ming-Shao Tsai
Journal:  Int J Environ Res Public Health       Date:  2021-06-24       Impact factor: 3.390

5.  Deep Neck Infection Risk in Patients with Sleep Apnea: Real-World Evidence.

Authors:  Meng-Chang Ding; Cheng-Ming Hsu; Stanley Yung-Chuan Liu; Yi-Chan Lee; Yao-Hsu Yang; Chia-Yen Liu; Geng-He Chang; Yao-Te Tsai; Li-Ang Lee; Pei-Rung Yang; Hsueh-Yu Li; Ming-Shao Tsai
Journal:  Int J Environ Res Public Health       Date:  2021-03-19       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.